Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades: Impact of evidence-based management

Gabriele Castelli, Alessandra Fornaro, Mauro Ciaccheri, Alberto Dolara, Vito Troiani, Benedetta Tomberli, Iacopo Olivotto, Gian Franco Gensini

Research output: Contribution to journalArticle

Abstract

Background-Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure. However, limited evidence is available specifically on idiopathic dilated cardiomyopathy. We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years. Methods and Results-From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years. Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001- 2011 (n=238). Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P

Original languageEnglish
Pages (from-to)913-921
Number of pages9
JournalCirculation: Heart Failure
Volume6
Issue number5
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Dilated Cardiomyopathy
Survival Rate
Heart Failure
Angiotensin Receptor Antagonists
Coronary Angiography
Angiotensin-Converting Enzyme Inhibitors
Stroke Volume
Equipment and Supplies
Survival
Therapeutics

Keywords

  • Cardiac resynchronization therapy
  • Cardiomyopathy
  • Dilated
  • Drug therapy
  • Heart failure
  • Outcomes assessment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades : Impact of evidence-based management. / Castelli, Gabriele; Fornaro, Alessandra; Ciaccheri, Mauro; Dolara, Alberto; Troiani, Vito; Tomberli, Benedetta; Olivotto, Iacopo; Gensini, Gian Franco.

In: Circulation: Heart Failure, Vol. 6, No. 5, 09.2013, p. 913-921.

Research output: Contribution to journalArticle

Castelli, Gabriele ; Fornaro, Alessandra ; Ciaccheri, Mauro ; Dolara, Alberto ; Troiani, Vito ; Tomberli, Benedetta ; Olivotto, Iacopo ; Gensini, Gian Franco. / Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades : Impact of evidence-based management. In: Circulation: Heart Failure. 2013 ; Vol. 6, No. 5. pp. 913-921.
@article{e80b1e2c3f6b49c8a77fb2a369972025,
title = "Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades: Impact of evidence-based management",
abstract = "Background-Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure. However, limited evidence is available specifically on idiopathic dilated cardiomyopathy. We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years. Methods and Results-From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73{\%} men; left ventricular ejection fraction, 32±10{\%}) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years. Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001- 2011 (n=238). Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56{\%}, 12{\%}, 8{\%} (period 1) to 97{\%}, 86{\%}, 17{\%} (period 4), respectively (P",
keywords = "Cardiac resynchronization therapy, Cardiomyopathy, Dilated, Drug therapy, Heart failure, Outcomes assessment",
author = "Gabriele Castelli and Alessandra Fornaro and Mauro Ciaccheri and Alberto Dolara and Vito Troiani and Benedetta Tomberli and Iacopo Olivotto and Gensini, {Gian Franco}",
year = "2013",
month = "9",
doi = "10.1161/CIRCHEARTFAILURE.112.000120",
language = "English",
volume = "6",
pages = "913--921",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany over 3 decades

T2 - Impact of evidence-based management

AU - Castelli, Gabriele

AU - Fornaro, Alessandra

AU - Ciaccheri, Mauro

AU - Dolara, Alberto

AU - Troiani, Vito

AU - Tomberli, Benedetta

AU - Olivotto, Iacopo

AU - Gensini, Gian Franco

PY - 2013/9

Y1 - 2013/9

N2 - Background-Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure. However, limited evidence is available specifically on idiopathic dilated cardiomyopathy. We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years. Methods and Results-From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years. Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001- 2011 (n=238). Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P

AB - Background-Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure. However, limited evidence is available specifically on idiopathic dilated cardiomyopathy. We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years. Methods and Results-From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years. Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001- 2011 (n=238). Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P

KW - Cardiac resynchronization therapy

KW - Cardiomyopathy

KW - Dilated

KW - Drug therapy

KW - Heart failure

KW - Outcomes assessment

UR - http://www.scopus.com/inward/record.url?scp=84887490363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887490363&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.112.000120

DO - 10.1161/CIRCHEARTFAILURE.112.000120

M3 - Article

C2 - 23888044

AN - SCOPUS:84887490363

VL - 6

SP - 913

EP - 921

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 5

ER -